Compare NTNX & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NTNX | QGEN |
|---|---|---|
| Founded | 2009 | 1986 |
| Country | United States | Netherlands |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.9B | 10.2B |
| IPO Year | 2015 | 1998 |
| Metric | NTNX | QGEN |
|---|---|---|
| Price | $39.42 | $41.28 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 9 |
| Target Price | ★ $64.06 | $51.30 |
| AVG Volume (30 Days) | ★ 2.9M | 1.7M |
| Earning Date | 05-27-2026 | 05-06-2026 |
| Dividend Yield | N/A | ★ 6.01% |
| EPS Growth | ★ 227.45 | N/A |
| EPS | ★ 0.57 | N/A |
| Revenue | ★ $2,537,927,000.00 | N/A |
| Revenue This Year | $13.60 | $8.18 |
| Revenue Next Year | $13.18 | $5.71 |
| P/E Ratio | $69.20 | ★ $24.01 |
| Revenue Growth | ★ 18.11 | N/A |
| 52 Week Low | $35.39 | $38.80 |
| 52 Week High | $83.36 | $57.82 |
| Indicator | NTNX | QGEN |
|---|---|---|
| Relative Strength Index (RSI) | 49.90 | 45.28 |
| Support Level | $37.87 | $38.80 |
| Resistance Level | $42.50 | $48.80 |
| Average True Range (ATR) | 1.80 | 0.83 |
| MACD | 0.15 | 0.44 |
| Stochastic Oscillator | 51.54 | 84.09 |
Nutanix Inc is engaged in cloud software, offering organizations a single platform for running applications and managing data anywhere. Its Nutanix Cloud Platform is designed to enable organizations to build a hybrid multicloud infrastructure, providing a consistent cloud operating model with a single platform for running applications and managing data in core data centers, at the edge, and in public clouds, all while supporting a variety of hypervisors and container platforms. The company operates a single operating and reportable segment based on a subscription business model. It conducts business in the United States, Europe, the Middle East and Africa, Asia Pacific, and other Americas, with key revenue generated from the United States.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2024 sales), followed by EMEA (33%), and the Asia-Pacific (15%).